贝伐单抗：适用于所有季节的一种治疗方法？ - Suppr

Suppr

超能文献

Bevacizumab: one treatment for all the seasons?

作者信息

Gelibter Alain J, Di Segni Susanna, Zeuli Massimo, Cognetti Francesco

出版信息

J Clin Oncol. 2008 Jan 20;26(3):511; author reply 511-2. doi: 10.1200/JCO.2007.15.0292.

DOI:10.1200/JCO.2007.15.0292

PMID:18202430

Abstract

摘要

相似文献

Bevacizumab: one treatment for all the seasons?

J Clin Oncol. 2008 Jan 20;26(3):511; author reply 511-2. doi: 10.1200/JCO.2007.15.0292.

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Nat Rev Drug Discov. 2004 May;3(5):391-400. doi: 10.1038/nrd1381.

Bevacizumab beyond progression: does this make sense?

J Clin Oncol. 2008 Nov 20;26(33):5313-5. doi: 10.1200/JCO.2008.17.4540. Epub 2008 Oct 14.

Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.

Clin Colorectal Cancer. 2006 Sep;6(3):189-91. doi: 10.1016/S1533-0028(11)70281-X.

[New medications; bevacizumab].

Ned Tijdschr Geneeskd. 2006 Oct 7;150(40):2194-5.

[PZ Innovation Prize for Avastin: Bevacizumab--new therapy option in colon carcinoma].

Krankenpfl J. 2005;43(7-10):234.

Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.

Oncologist. 2007 Apr;12(4):443-50. doi: 10.1634/theoncologist.12-4-443.

Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer.

Oncology. 2005;69 Suppl 3:1-3. doi: 10.1159/000088477. Epub 2005 Nov 21.

The horizon of antiangiogenic therapy for colorectal cancer.

Oncology (Williston Park). 2005 Mar;19(3):297-306; discussion 306, 308, 317-33.

Bevacizumab.

Nat Rev Drug Discov. 2005 May;Suppl:S8-9. doi: 10.1038/nrd1727.

引用本文的文献

Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice.

Transl Lung Cancer Res. 2015 Feb;4(1):27-35. doi: 10.3978/j.issn.2218-6751.2014.11.03.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Bevacizumab: one treatment for all the seasons?

J Clin Oncol. 2008 Jan 20;26(3):511; author reply 511-2. doi: 10.1200/JCO.2007.15.0292.

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Nat Rev Drug Discov. 2004 May;3(5):391-400. doi: 10.1038/nrd1381.

Bevacizumab beyond progression: does this make sense?

J Clin Oncol. 2008 Nov 20;26(33):5313-5. doi: 10.1200/JCO.2008.17.4540. Epub 2008 Oct 14.

Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.

Clin Colorectal Cancer. 2006 Sep;6(3):189-91. doi: 10.1016/S1533-0028(11)70281-X.

[New medications; bevacizumab].

Ned Tijdschr Geneeskd. 2006 Oct 7;150(40):2194-5.

[PZ Innovation Prize for Avastin: Bevacizumab--new therapy option in colon carcinoma].

Krankenpfl J. 2005;43(7-10):234.

Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.

Oncologist. 2007 Apr;12(4):443-50. doi: 10.1634/theoncologist.12-4-443.

Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer.

Oncology. 2005;69 Suppl 3:1-3. doi: 10.1159/000088477. Epub 2005 Nov 21.

The horizon of antiangiogenic therapy for colorectal cancer.

Oncology (Williston Park). 2005 Mar;19(3):297-306; discussion 306, 308, 317-33.

Bevacizumab.

Nat Rev Drug Discov. 2005 May;Suppl:S8-9. doi: 10.1038/nrd1727.

引用本文的文献

Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice.

Transl Lung Cancer Res. 2015 Feb;4(1):27-35. doi: 10.3978/j.issn.2218-6751.2014.11.03.